The Application of Wide Pulse High Frequency Neuromuscular Electrical Stimulation in Disorders Associated With Motoneuron Hyperexcitability (MnHyperex)

In the present project, the investigators aim at proposing innovative ways of investigating spinal motoneuron hyperexcitability to counteract the associated impairments by using wide pulse high frequency neuromuscular electrical stimulation (WPHF NMES) in various populations. The investigators will use WPHF NMES contractions as a model to gain insights into the mechanisms underlying muscle cramps, restless legs syndrome or stroke-induced spasticity as there is evidence that they share common underlying mechanisms. The investigators will then use WPHF NMES as a training modality to improve plantar flexor neuromuscular function in stroke patients by taking advantage of their motoneuronal hyperexcitability.

Study Overview

• Status: Recruiting
• Conditions: Stroke; Restless Legs Syndrome; Healthy Volunteers; Cramp
• Intervention / Treatment: Other: wide pulse high frequency neuromuscular electrical stimulation training

• Study Type: Interventional
• Enrollment (Estimated): 110
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Nicolas Place, PhD; Phone Number: +41216923806; Email: nicolas.place@unil.ch

Study Locations

• Switzerland
  • Lausanne, Switzerland, 1015
    • Recruiting
    • Bâtiment Synathlon, quartier UNIL-Centre
    • Contact: Nicolas Place, PhD; Phone Number: 0216923806; Email: nicolas.place@unil.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

STROKE PATIENTS:

• Diagnosis of first-ever stroke (ischemic or hemorrhagic) with unilateral motor deficits from at least 6 months. Stroke will have to be confirmed from medical records and/or radiological imaging (CT scan or MRI)
• Inadequate ankle control during gait defined as ankle dorsiflexion less than 5° during stance phase and 0° during swing phase; 0° = ankle neutral position)
• Passive range of motion of ankle dorsiflexion at least to neutral position
• Ability to walk at least 10 m with or without assistive devices
• Spasticity at the triceps surae (either soleus and/or gastrocnemii) considered as a Modified Ashworth Sore ≥1
• Being available for the study period and willing to participate
• No contraindication to neuromuscular electrical stimulation

Contraindications for stroke patients:

• Surface sensory loss of affected lower leg (defined as incapacity to feel the 60-g touch using the Semmes-Weinstein monofilament test)
• Patients unable to understand indications or to provide informed consent
• A history of orthopedic or other neurological disorders affecting walking function
• A history of surgery to correct drop foot (ankle fixation)
• Patients under antispastic medication (baclofen, tizanidine, tolperisone, benzodiazepines, dantrolene or botulinum toxin to the plantar flexor muscles in the last 6 months).

PEOPLE PRONE TO MUSCLE CRAMPS:

• Reporting nocturnal muscle cramps (the assessment will be done through a questionnaire)
• Not being treated for muscle cramps
• Being available for the study period and willing to participate
• No contraindication to neuromuscular electrical stimulation

PATIENTS WITH RESTLESS LEGS SYNDROME:

To be included in the study, RLS patients will have to satisfy the Diagnostic criteria for RLS published by the International Restless Legs Syndrome StudyGroup (IRLSSG). All five key clinical features are required for the diagnosis:

• An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. Sometimes the urge to move is present without the uncomfortable sensations, and sometimes the arms or other body parts are involved in addition to the legs.
• The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
• The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
• The urge to move or unpleasant sensations are worse in the evening or night than during the day, or only occur in the evening or night. When symptoms are severe, the worsening at night may not be noticeable but must have been previously present.
• Symptoms are not solely accounted for by another medical or behavioral condition, such as leg cramps or habitual foot tapping.
• No contraindication to neuromuscular electrical stimulation

They will also have to satisfy the following criteria:

• Diagnosis of primary RLS corresponding to:

  1. The presence of periodic limb movements
  2. A dopaminergic treatment response
  3. The presence of RLS in first-degree relatives
  4. A lack of profound daytime sleepiness
• Being available for the study period and willing to participate

HEALTHY PARTICIPANTS:

• No neurological disease
• No contraindication to neuromuscular electrical stimulation
• Being available for the study period and willing to participate

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Stroke patients - training group; Participants in this group will take part in a 6-week WPHF NMES training period and plantar flexor neuromuscular function will be assessed before and after training.	Other: wide pulse high frequency neuromuscular electrical stimulation training; Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks
No Intervention: stroke patients - control group; Participants in this group will keep their daily life activities for 6 weeks and plantar flexor neuromuscular function will be assessed before and after training.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in maximal voluntary contraction force	Change from baseline maximal voluntary contraction force after the six-week training period in stroke patients	through study completion, an average of 8 weeks
Change in NMES-evoked force	Change from baseline NMES-evoked force after the six-week training period	through study completion, an average of 8 weeks
NMES-evoked force	Comparison of NMES-evoked force in plantar flexor muscles between patients (prone to cramps or restless legs) and healthy volunteers	through study completion, an average of 2 weeks
Change in estimates of persistent inward current (Delta F assessed with high-density surface electromyography and/ or the torque measured during vibration after the last bout of NMES)	Change from baseline estimates of persistent inward current after the six-week training period in stroke patients	through study completion, an average of 8 weeks
Estimates of persistent inward current (Delta F assessed with high-density surface electromyography and/ or the torque measured during vibration after the last bout of NMES)	comparison of estimates of persistent inward current strength in plantar flexor muscles between patients (prone to cramps or restless legs) and healthy volunteers	through study completion, an average of 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in voluntary activation level and contractile properties of the plantar flexor muscles	Change from baseline voluntary activation level and contractile properties of the plantar flexor muscles after the six-week training period in stroke patients	through study completion, an average of 8 weeks
voluntary activation level and contractile properties of the plantar flexor muscles	comparison of voluntary activation level and contractile properties of the plantar flexor muscles between patients (prone to cramps or restless legs) and healthy volunteers	through study completion, an average of 2 weeks
change in spasticity at the ankle joint level for stroke patients	Change from baseline Ashworth scale score (minimal score 0, maximal score 4, a higher score means a worst outcome) after the six-week training period in stroke patients	through study completion, an average of 8 weeks
10-m walking test (s)	functional test	through study completion, an average of 8 weeks
6-min walking test (m)	functional test	through study completion, an average of 8 weeks
time up and go test (s)	functional test	through study completion, an average of 8 weeks
Change in spinal excitability in stroke patients	change from baseline soleus Hoffmann reflex amplitude after the six-week training period in stroke patients	through study completion, an average of 8 weeks
Spinal excitability	comparison of soleus Hoffmann reflex amplitude between patients (prone to cramps or restless legs) and healthy volunteers	through study completion, an average of 2 weeks
Cramp threshold frequency (CTF) for cramp-prone individuals	comparison between participants reporting muscle cramps and healthy volunteers	through study completion, an average of 2 weeks

Collaborators and Investigators

• Sponsor: University of Lausanne
• Collaborators: Swiss National Science Foundation

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2023
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: May 16, 2023
• First Submitted That Met QC Criteria: June 8, 2023
• First Posted (Actual): June 18, 2023

Study Record Updates

• Last Update Posted (Actual): November 28, 2023
• Last Update Submitted That Met QC Criteria: November 27, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: muscle strength; training; persistent inward current
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Parasomnias; Restless Legs Syndrome
• Other Study ID Numbers: 2022-01817

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No